Pierre Broqua

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 721 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

Zoe Boyer‐Díaz, Peio Aristu-Zabalza, María Andrés‐Rozas et al. · Journal of Hepatology · 2020 · 163 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis

Guillaume Wettstein, Jean‐Michel Luccarini, Laurence Poekes et al. · Hepatology Communications · 2017 · 130 citations · Full text

Medicine, Biochemistry, Pharmacology +17

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate

Benaı̈ssa Boubia, Olivia Poupardin, Martine Barth et al. · Journal of Medicinal Chemistry · 2018 · 106 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis

Nadira Ruzehaji, C. Frantz, Matthieu Ponsoye et al. · Annals of the Rheumatic Diseases · 2016 · 96 citations · Full text

Medicine, Dermatology, Pharmacology +17